Prostate-specific antigen (PSA) has been established within the last 30 years for prostate cancer (PCa) management and the detection of its molecular forms including free PSA (fPSA) in the early 1990s [1, 2] enhanced specificity [3]. This evidence concerns the gene KLK3 and prostate carcinoma.